Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer’s Tofacitinib Clears FDA Without Limited Indication

This article was originally published in The Pink Sheet Daily

Executive Summary

With FDA’s early approval of tofacitinib for rheumatoid arthritis – the first JAK inhibitor and, unlike the popular TNF inhibitors, an oral agent – the agency appears to have sided with Pfizer on many issues left up in the air after an advisory committee review.

Advertisement

Related Content

Could FDA Force Pfizer To Push Shingles Vaccination With Xeljanz Psoriatic Arthritis Approval?
Pfizer's Xeljanz: The Slow Road To Blockbuster Status
Beyond Xeljanz: An Inflammation & Immunology Portfolio Blooms At Pfizer
Pfizer’s Xeljanz In Psoriasis Does Best At Dose That Worried FDA
Pfizer’s Xeljanz In Psoriasis Does Best At Dose That Worried FDA
India’s Drug Advisory Body Calls For Larger Study To Approve Pfizer’s Xeljanz
India’s Drug Advisory Body Calls For Larger Study To Approve Pfizer’s Xeljanz
Approval Recommendations Set Path For Pfizer’s Xeljanz, Japan Tobacco’s HIV Therapy In Japan
Will Pharmacovigilance Be Enough To Address Questions About Pfizer’s Tofacitinib?
Panel Backs Pfizer’s Tofacitinib For RA, With Narrower Indication

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS073587

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel